ARHGEF35: A Potential Drug Target and Biomarker (G445328)

Target Name: ARHGEF35

NCBI ID: G445328

ARHGEF35

ARHGEF35: A Potential Drug Target and Biomarker

Introduction

ARHGEF35 (Rho guanine nucleotide exchange factor 35) is a protein that plays a critical role in the regulation of cell signaling pathways, including the G-protein-coupled receptor (GPCR) signaling pathway. GPCR is a family of transmembrane proteins that play a central role in cellular signaling, providing targets for drugs and therapies to modulate various cellular processes. The loss of GPCR signaling pathway has been implicated in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

The discovery of ARHGEF35 as a potential drug target and biomarker has significant implications for the development of new therapies. By targeting ARHGEF35, researchers may be able to treat conditions that are currently treated with little to no efficacy, or may be able to improve the efficacy of existing therapies. Additionally, the identification of ARHGEF35 as a potential biomarker may have the potential to aid in the development of personalized medicine, where treatments are tailored to an individual's specific genetic makeup.

Understanding the Structure and Function of ARHGEF35

The ARHGEF35 protein is a 21-kDa protein that belongs to the ARHGEF family of proteins. The ARHGEF family is characterized by the presence of a GTP-binding protein domain and a nucleotide exchange factor domain. The GTP-binding protein domain is responsible for the binding of GTP, while the nucleotide exchange factor domain is responsible for the exchange of nucleotides between specific DNA sequences.

ARHGEF35 is expressed in various tissues and cells, including neurons, cardiac cells, and blood vessels. It has been shown to play a role in the regulation of GPCR signaling pathways, specifically in the regulation of the trafficking of GPCR proteins to the endoplasmic reticulum ( ER) and in the regulation of the stability of GPCR complexes in the ER.

In addition to its role in GPCR signaling, ARHGEF35 has also been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and survival. It has been shown to interact with various protein partners, including the transcription factor NF-kappa-B and the protein kinase ALCAT3.

The Potential Therapeutic Applications of ARHGEF35

The identification of ARHGEF35 as a potential drug target and biomarker has significant implications for the development of new therapies. By targeting ARHGEF35, researchers may be able to treat conditions that are currently treated with little to no efficacy, or may be able to improve the efficacy of existing therapies.

One therapeutic potential application of ARHGEF35 is the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The loss of GPCR signaling pathway has been implicated in the development and progression of these diseases, and targeting ARHGEF35 may be a promising approach to treating these conditions.

Another therapeutic potential application of ARHGEF35 is the treatment of psychiatric disorders, such as depression and anxiety. The regulation of GPCR signaling pathway is involved in the neurotransmitter systems that are responsible for mood and anxiety regulation, and targeting ARHGEF35 may be a promising approach to treating these disorders.

In addition to its potential therapeutic applications, the identification of ARHGEF35 as a potential drug target and biomarker also has the potential to aid in the development of personalized medicine, where treatments are tailored to an individual's specific genetic makeup. By using CRISPR/Cas9 technology to identify and manipulate specific genes, researchers may be able to use ARHGEF35 as a biomarker to predict the response of

Protein Name: Rho Guanine Nucleotide Exchange Factor 35

The "ARHGEF35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets